13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Synaptic Plasticity
Synaptic plasticity, the cornerstone of the brain's adaptability and learning prowess, refers to the dynamic changes occurring at neuronal junctions in response to activity. Long-term potentiation (LTP) and long-term depression (LTD) represent pivotal facets of synaptic plasticity, orchestrating the strengthening and weakening of synaptic connections, respectively. These mechanisms are fundamental to encoding and retaining information, forming the bedrock of memory and learning. However, dysregulation of synaptic plasticity is implicated in various neurological and psychiatric disorders, including Alzheimer's disease, schizophrenia, depression, and addiction, underscoring its significance in understanding disease pathogenesis and treatment development. Researchers are fervently exploring innovative strategies to modulate synaptic plasticity, aiming to rectify aberrant synaptic function in diseased states. By elucidating these mechanisms, targeted interventions could emerge, offering hope for ameliorating neural deficits associated with such disorders and enhancing patient outcomes.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States